CD274 and cholangiocarcinoma: Additionally, a recent TOPAZ-1 clinical trial (Retrieved 6 December 2022, from ClinicalTrial.gov, NCT03875235) demonstrated that durvalumab can additionally improve the efficacy of chemotherapy in cholangiocarcinoma, demonstrating PD-L1 blockade’s potential as a first-line agent in advanced cholangiocarcinoma [13].